Summit Therapeutics Inc.

Summit Therapeutics Inc. announced the approval and filing of an amendment to its Restated Certificate of Incorporation to increase authorized common stock by 1 billion shares. This follows a significant $2.0 billion strategic equity investment from AstraZeneca. The company also reported its third-quarter financial results, with a GAAP net loss of $208.4 million and $629.8 million in cash and investments. Key clinical developments for ivonescimab continue, with an FDA PDUFA date set for November 14, 2026.

Summit Therapeutics Inc. announced the expansion of its global registration-enabling clinical development program for ivonescimab into urothelial carcinoma (bladder cancer). The company is initiating the global, multi-regional Phase II/III HARMONi-GU1 trial, which will evaluate ivonescimab plus enfortumab vedotin (EV) against pembrolizumab plus EV as first-line therapy for locally advanced or metastatic urothelial carcinoma. Global clinical trial site activations are planned to commence by Q4 2026, further broadening ivonescimab's potential applications.

Summit Therapeutics Inc. has entered into a distribution agreement with J.P. Morgan Securities LLC to potentially sell up to $380,000,000 of its common stock. This "at the market" offering allows the company to raise capital from time to time, with J.P. Morgan acting as the sales agent and earning a commission of up to 3.0%. The company retains the flexibility to decide if and when to sell shares, with no obligation to do so.

Summit Therapeutics reported a net loss of $215.7 million for the second quarter of 2026 and $405.1 million for the first six months. The company explicitly stated that its current cash and short-term investments are not sufficient to fund operations for at least one year, raising substantial doubt about its ability to continue as a going concern. Summit raised $227.4 million through an at-the-market offering and received an upfront payment of $0.5 million from the sale of its ridinilazole asset.

Summit Therapeutics reported Q2 2026 financial results and significant clinical progress for ivonescimab. The HARMONi-6 trial demonstrated a statistically significant overall survival benefit (HR 0.66) in 1L squamous NSCLC, marking the first such achievement over an anti-PD-(L)1 regimen. An updated HARMONi analysis showed consistent overall survival (HR 0.76) across Western and Asian patients in EGFRm NSCLC. The company ended the quarter with $690.7 million in cash and investments, while non-GAAP operating expenses increased to $151.8 million due to expanded clinical studies.

Summit Therapeutics announced updated overall survival (OS) analysis results from its global Phase III HARMONi clinical trial for ivonescimab in EGFR-mutated non-small cell lung cancer. The analysis, with a June 2026 data cutoff, showed a consistent OS trend with a hazard ratio of 0.76 for the full population and western patient subgroups. The drug maintained an acceptable and manageable safety profile, and these results have been provided to the FDA, which has a PDUFA goal action date of November 14, 2026, for the Biologics License Application.

Summit Therapeutics Inc.'s Audit Committee and all independent directors have approved company affiliates to purchase shares of common stock under its existing at-the-market (ATM) offering. Separately, Co-Chief Executive Officers Robert Duggan and Mahkam Zanganeh, along with Chief Operating Officer and Chief Financial Officer Manmeet Soni, have indicated their likely intent to purchase shares under the ATM in the near term, though no specific number of shares or binding commitments have been made.

Summit Therapeutics announced positive overall survival (OS) results from the Phase III HARMONi-6 trial for ivonescimab in first-line squamous non-small cell lung cancer (NSCLC), conducted by its partner Akeso in China. Ivonescimab plus chemotherapy reduced the risk of death by 34% (HR 0.66) compared to tislelizumab plus chemotherapy, with 24-month OS rates of 64.7% vs. 48.6%. Additionally, encouraging global Phase II data for ivonescimab in first-line metastatic colorectal cancer (mCRC) from the AK112-206 trial showed an objective response rate (ORR) of 70.8% and a manageable safety profile. The company will discuss these results in a conference call.

Summit Therapeutics Inc. reported a significant net loss of $189.4 million for the first quarter of 2026, a substantial increase from the prior year, driven by higher research and development and general and administrative expenses. The company's cash and cash equivalents declined significantly, leading management to express substantial doubt about its ability to continue as a going concern. Summit is focused on the development of its lead candidate, ivonescimab, and is evaluating options to raise additional capital.

Summit Therapeutics Inc. reported its Q1 2026 financial results and provided significant clinical updates for ivonescimab. Key highlights include the upcoming presentation of HARMONi-6 overall survival data at the ASCO 2026 Plenary Session and the FDA's acceptance of the Biologics License Application (BLA) for ivonescimab with a PDUFA date of November 14, 2026. The company also updated on HARMONi-3 trial progress, expecting final PFS data for the squamous cohort in H2 2026 and for the non-squamous cohort in H1 2027. Financially, Summit reported a GAAP net loss of $(189.4) million and a non-GAAP net loss of $(116.6) million for the quarter, with cash and short-term investments totaling $598.7 million.